Biotech Déjà vu – Insider Weekends

Ardelyx Inc. (ARDX): $5.52

Market Cap: $1.31B

Enterprise Value: $1.25B

Key Insights:

• It felt like we experienced déjà vu last week when we saw the biopharmaceutical company, Ardelyx (ARDX), find its way into our list of top insider purchases.
• Ardelyx reminds us a lot of Avadel Pharmaceuticals (AVDL) in the sense that both companies have benefited from  new drug launches and this is reflected in their financials.
• Both companies appear to be at an inflection point with revenue growing quarter over quarter and net losses reducing over time to a level where they will likely see profitability in the next quarter or two.

Only plus or premium subscribers can access this post. Subscribe today.